Research programme: osteoporosis therapy - CollaGenex

Drug Profile

Research programme: osteoporosis therapy - CollaGenex

Alternative Names: Osteoporosis therapy research programme - CollaGenex

Latest Information Update: 04 Feb 2008

Price : $50

At a glance

  • Originator CollaGenex Pharmaceuticals
  • Class
  • Mechanism of Action Collagenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 18 Mar 2003 No development reported - Preclinical for Osteoporosis in USA (unspecified route)
  • 12 May 2000 CollaGenex Pharmaceuticals intends to pursue this research through partnership with another company
  • 10 Feb 2000 Preclinical development for Osteoporosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top